Tuesday, September 20, 2016

BRIEF-Mast reports top-line results from phase 3 study in Sickle Cell Disease

* No statistically significant differences between treatment

groups in intent-to-treat population across 2 secondary efficacy

endpoints

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)